Research guide · Anti-Aging & Longevity
Fox04 DRI — research protocol
Advanced senolytic peptide studied for clearance of senescent cells and longevity research.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Senolytic D-retro-inverso peptide
- Lyophilized powder for stability
- 99% HPLC verified purity
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
FOXO4-DRI is a lab-made peptide studied as a senolytic compound, designed to clear out old, damaged senescent cells. It disrupts the FOXO4-p53 interaction, allowing p53 to trigger apoptosis in these cells.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| FOXO4-DRI | 5 mg/kg | repeated over weeks | over weeks | intraperitoneal |
Cycle: Not specified in the text; protocols are repeated over weeks.
Benefits and research observations: Peptide enters circulation within hours, senescent cells begin apoptosis in 1-3 days, immune system clears debris in 3-14 days, and tissue microenvironment improves in 2-6 weeks. Monitor hs-CRP, IL-6, IGF-1, and metabolic panel.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Baar MP, et al. Cell, 2017.
- 2.Le HH, et al. Aging Cell, 2021.